Ascletis Pharma has dosed the first participants in a US Phase II trial of ASC30, an oral small molecule glucagon-like ...

Eisai and Biogen have announced that the US Food and Drug Administration (FDA) has accepted for review the supplemental ...

LEQEMBI is currently approved in 53 countries and regions and is under regulatory review in 7 countries. In August 2025, the US FDA approved LEQEMBI IQLIK 360 mg for weekly subcutaneous maintenance ...

The U.S. Food and Drug Administration has approved the Zycubo (copper histidinate) injection as the first treatment for ...

The new generic drug has been approved for treatment of bovine respiratory disease and associated pyrexia in beef and ...

If approved, LEQEMBI IQLIK would be the first and only anti-amyloid treatment to offer at-home injection options for initiation and maintenance dosing for this progressive, relentless disease FDA acti ...

The updated labeling was supported by modeling data and in vivo results from the Dose Optimization study (see graph) and the ...

The phase 3b TOGETHER-PsA trial evaluated the safety and efficacy of concomitant ixekizumab and tirzepatide in adults with active psoriatic arthritis and obesity.

For adolescents diagnosed with episodic migraine, fremanezumab seems to yield greater reduction in migraine and headache days.

The FDA has approved nixiFLOR, the first generic florfenicol-flunixin injectable, for treatment of bovine respiratory disease and control of associated fever in beef and nonlactating dairy cattle.

LEO Pharma A/S, a global leader in medical dermatology, today announced it will present 23 scientific posters at Maui Derm ...

The new 5.5ml BD Neopak XtraFlow Syringe uses BD’s advanced technologies, including thinner cannulas.